Opinion|Videos|July 30, 2024
Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications
The panel addresses the intricacies of treating patients with chronic lymphocytic leukemia who experience treatment resistance.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Briefly discuss insights regarding emerging resistance data and its potential implications on treatment decisions/practices.
- In patients who progress on 1L therapy with BTKi, do you test for the presence of BTK resistance mutations?
- How do you interpret available data to the clinical practice setting?
Advertisement
Related to this article
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
2
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
5